AZAMIAN BOBAK R. (President and CEO) sold 1.2% of their position (10K shares) of TARSUS PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $615.5K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 6/22/2026ACC: 0001827672-26-000009
DirectorOfficer10% Owner· President and CEO
Since Oct 2020
-10K
Net shares
Net seller
$615.5K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
10K disposed
Non-Derivative Transactions2
Common Stock
Indirect
Shares
−4.58K
Price / share
$61.24
Trade value
$280.60K
% of position
0.5%
6/17/2026
857.99K→853.41K
Common Stock
Indirect
Shares
−5.42K
Price / share
$61.81
Trade value
$334.89K
% of position
0.6%
6/17/2026
853.41K→847.99K
Total
Net shares
−10K
Net value
-$615.49K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 6/17/2026 | S · Sale | −4.58K | $61.24 | $280.60K | 0.5% | 857.99K | 853.41K |
| Common Stock Indirect | 6/17/2026 | S · Sale | −5.42K | $61.81 | $334.89K | 0.6% | 853.41K | 847.99K |
| Total | −10K | -$615.49K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
DirectShares owned33.42K
Total
33.42K direct33.42K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 33.42K | Direct |
| Total | 33.42K | 33.42K direct |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported